Skip to main content
. 2015 Oct;3(10):778–786. doi: 10.1016/S2213-8587(15)00219-3

Table 2.

Primary and birth outcomes

Placebo group
Metformin group
Adjusted mean difference or OR (95 % CI) p value
Mean (SD) or n (%) N Mean (SD) or n (%) N
Primary outcome
Z score of birthweight percentile* 0·2680 (1·0055) 220 0·2464 (1·0179) 214 −0·029 (−0·217 to 0·158) 0·76
Birth outcome (all births)
Livebirth at ≥24 weeks' gestation 220 (99%) 222 214 (97%) 221 .. ..
Stillbirth at ≥24 weeks' gestation, miscarriage, or termination of pregnancy 2 (1%) 222 7 (3%) 221 3·597 (0·739 to 17·504)§ 0·11
Birth outcome (liveborn babies at ≥24 weeks' gestation)
Gestational age at delivery (days) 275·9 (15·9) 220 276·6 (11·7) 214 .. ..
Male sex 109 (50%) 220 109 (51%) 214 .. ..
Birthweight at delivery (g) 3463 (660) 220 3462 (548) 214 .. ..
Birthweight percentile 57·3 (27·9) 220 56·9 (28·6) 214 .. ..

OR=odds ratio.

*

Percentile by gestational age, sex, and parity for livebirths at ≥24 weeks' gestation.

Two terminations of pregnancy, one for fetal abnormality (split hand and foot syndrome) and one after a spontaneous membrane rupture at 18 weeks' gestation.

Of the two stillbirths, one was at 31 weeks of a baby with a known cardiac anomaly and severe hydrops fetalis and one was an intrauterine death of a normally formed baby born at 38 weeks with a birthweight less than the third percentile for gestation. Of the four miscarriages, one was after a road traffic accident and three were spontaneous. One termination of pregnancy was done after a diagnosis of trisomy 21. None of the women returned diaries nor provided a blood sample for analysis of metformin.

§

OR from post-hoc analysis.

HHS Vulnerability Disclosure